Prosecution Insights
Last updated: April 19, 2026

Examiner: HSU, GRACE CHING

Tech Center 1600 • Art Units: 1624 1627

This examiner grants 75% of resolved cases

Performance Statistics

75.0%
Allow Rate
+15.0% vs TC avg
62
Total Applications
+27.3%
Interview Lift
1151
Avg Prosecution Days
Based on 36 resolved cases, 2023–2026

Rejection Statute Breakdown

1.9%
§101 Eligibility
18.2%
§102 Novelty
18.2%
§103 Obviousness
42.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18533710 SOLID FORMS OF (3R)-N-[2-CYANO-4-FLUORO-3-(3-METHYL-4-OXO-QUINAZOLIN-6-YL)OXY-PHENYL]-3-FLUORO-PYRROLIDINE-1-SULFONAMIDE Non-Final OA Hoffmann-La Roche Inc.
18076274 NOVEL IMIDAZOPYRAZINE DERIVATIVES Non-Final OA Hoffmann-La Roche Inc.
17794314 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND THERAPEUTIC PHARMACEUTIC COMPOSITION COMPRISING SAME Non-Final OA KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
17995388 CRYSTALLINE FORMS OF 4-[(7-CHLORO-2-METHOXYBENZO[B][1,5]NAPHTHYRIDIN-10-YL)AMINO]-2,6-BIS(PYRROLIDIN-1-YLMETHYL)PHENOL AND SALTS THEREOF Final Rejection Merck Patent GmbH
17912300 DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY Non-Final OA H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
17757572 NOVEL USES Non-Final OA Intra-Cellular Therapies, Inc.
18302313 Heterocyclic Compounds as RET Kinase Inhibitors Non-Final OA Cancer Research Technology Limited
18563554 1,2-DIHYDROQUINOLINE-2-ONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY Non-Final OA ADMINISTRACIÓN GENERAL DE LA COMUNIDAD AUTÓNOMA DE EUSKADI
18556196 IL4I1 INHIBITORS AND METHODS OF USE Non-Final OA MSD R&D (CHINA) CO., LTD.
18556178 GPR35 Agonist Compounds Non-Final OA NXERA PHARMA UK LIMITED
17923754 Uses and Formulations of Cannabinoids Non-Final OA ADD Advanced Drug Delivery Technologies Ltd.
18554211 SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF Non-Final OA Sumitomo Pharma America, Inc.
18278715 SUBSTITUTED PYRIDINE-2,4-DIONE DERIVATIVES Non-Final OA SOTER BIOPHARMA PTE. LTD.
17592779 COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME Final Rejection Rigel Pharmaceuticals, Inc.
18320082 Photodynamic Therapy and Diagnosis Non-Final OA RMW CHO Group Limited
18015261 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Final Rejection SUZHOU ARK BIOPHARMACEUTICAL CO., LTD.
18001190 TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF Non-Final OA Delix Therapeutics, Inc.
17995327 ACTIVE SUBSTANCES FOR MEDICAL USE Final Rejection INFLAMED PHARMA GMBH

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month